TTA-A8
CAS No. : 1146395-46-1
| Size | Price | Stock |
|---|---|---|
| 1mg | $592 | Get quote |
| 5mg | $1301 | Get quote |
| 10mg | $1822 | Get quote |
| 50 mg | Get quote | |
| 100 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-14232 |
| M.Wt: | 430.42 |
| Formula: | C22H21F3N4O2 |
| Purity: | >98 % |
| Solubility: | 10 mM in DMSO |
TTA-A8 (Compound 13) is a short-acting T-type calcium channel antagonist with oral activity, exhibiting an IC50 value of 31.3 nM in the FLIPR depolarization assay. TTA-A8 possesses favorable pharmacokinetic properties, making it suitable for research on epilepsy and sleep[1].
In Vivo:TTA-A8 (3 mg/kg; p.o.; single dose) effectively shortened the duration of epileptic seizures in Wistar albino rats with genetic absence epilepsy. TTA-A8 (1-10 mg/kg; p.o.; single dose) significantly suppressed active wake and increased delta wave sleep in SD rats[1].
TTA-A8 (5 mg/kg; p.o.; single dose) exhibited moderate to high plasma clearance (CLp), low to moderate distribution volume (Vss), and short half-life (T1/2) across three preclinical species (rat, dog, rhesus)[1].
Pharmacokinetic parameters in rat, dog, rhesus[1]
| species | administration | dosage | CL (predicted)a(mL/min/kg) | CLp(observed)(mL/min/kg) | T1/2(h) | Vss (L/kg) | F (%) | plasma PB (% unbound)b |
| rat | p.o. | 5 mg/kg | 8 | 30.3 | 0.24 | 0.59 | 71 | 12.3 |
| dog | p.o. | 5 mg/kg | 13 | 11.8 | 0.81 | 0.36 | 23 | 15.5 |
| rhesus | p.o. | 5 mg/kg | 22 | 19.3 | 0.53 | 0.74 | 5 | 14.6 |